Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical and molecular assessment of regorafenib monotherapy.

Oncology reports - 1 Apr 2017

Kakizawa Nao, Suzuki Koichi, Fukui Taro, Takayama Yuji, Ichida Kosuke, Muto Yuta, Hasegawa Fumi, Watanabe Fumiaki, Kikugawa Rina, Tsujinaka Shingo, Futsuhara Kazushige, Miyakura Yasuyuki, Noda Hiroshi, Rikiyama Toshiki

Abstract excerpt

Regorafenib has shown survival benefits in metastatic colorectal cancer patients who were exacerbated after all standard therapies. Some patients, however, exhibit severe adverse events (AEs) resulting in treatment discontinuation. Therefore, the selection of patients likely to benefit from regorafenib is crucial. Twenty patients were treated with regorafenib for metastatic colorectal cancer; 122 plasma samples...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Pyridines
Share to Colorectal Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA, Neoplasm

Share to Neoplasm Metastasis

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins p21(ras)

Share to Survival Analysis

Share to Tomography, X-Ray Computed

Source

Identifiers

PMID: 28259999
DOI: 10.3892/or.2017.5456

Genes

KRAS
EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical and molecular assessment of regorafenib monotherapy.PMID 28259999Read ↗

Circulating Tumor DNA Dynamics and Treatment Outcome of Regorafenib in Metastatic Colorectal Cancer.Semantic proximity Read ↗

Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial).Semantic proximity Read ↗

[Regorafenib in patients with metastatic colorectal cancer: a review and an update].Semantic proximity Read ↗

Regorafenib Therapy as a Third-Line Treatment for Metastatic Colorectal Cancer: A Single Center Long Term ExperienceSemantic proximity Read ↗

Unexpected and durable response with regorafenib in a metastatic colorectal cancer patient without KDR mutation: A case report.Semantic proximity Read ↗

Durable Disease Control with Regorafenib in a Patient with Metastatic KIT-Mutated Colorectal Cancer.Semantic proximity Read ↗

Monitoring levels of circulating cell‐free DNA in patients with metastatic colorectal cancer as a potential biomarker of responses to regorafenib treatmentSemantic proximity Read ↗

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBECCA) nested within a compassionate use program.Semantic proximity Read ↗

A higher ctDNA fraction decreases survival in regorafenib‐treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot studySemantic proximity Read ↗

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.Semantic proximity Read ↗

Molecular insight of regorafenib treatment for colorectal cancer.Semantic proximity Read ↗

Regorafenib plus FOLFIRINOX as first-line treatment for patients with RAS-mutant metastatic colorectal cancer (FOLFIRINOX-R trial): a dose-escalation study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.